Search

Diphenylcyclopropenone (DCP) is a topically administered agent used for more than three decades for treatment of alopecia areata (AA). Moreover, numerous recent studies show it's efficiency in treatment of cutaneous metastatic melanoma. Despite being a potentially useful drug still very little is known about the pharmacokinetics of DCP. The authors investigated the stability of DCP solutions in propylene glycol with the addi- tion of 0.9% aquous solution of natrium chloride (0.9% NaCI) or with water. DCP was prepared in two concentrations: 0.1% and 3%. It's stability was then measured with different proportions of 0.9% NaCI or water added and in different temperatures. Contrary to common opinion that DCP solutions are extremely unstable, authors have found them to be relatively stable. DCP solutions with the addition of equal quantity of 0.9% NaCl decomposed slowly at the temperature of 37C but after 70 h all solutions still contained more than 80% of initial DCP. Solutions of DCP with the addition of 1% of water at the temperature of 4'C are in the present study stable, containing more than 98% of initial DCP after 20 days. Authors discuss the results in spite of possible metabolism of DCP on the surface of human skin during topical immunotherapy.

The aim of this study was to evaluate the chemical stability of diphenylcyclopropenone (DCP) in var- ious solvents. DCP is being used in topical therapy in patients with alopecia areata (AA). The solvents for DCP used so far were acetone, ethanol and propylene glycol. DCP is supposed to be an immune-modulating thera- peutic agent, however the studies on it's pharmacokinetics including chemical stability are lacking. In a pres- ent study, DCP was dissolved in acetone (A), ethanol (E), propylene glycol (PG) and isopropanol (I). Solutions at two concentrations: 0.1 and 3.0% were prepared in each of these solvents. Then, the solutions were divided into two parts - one'of which was stored at room temperature and the other in a refrigerator (at about 4⁰C) with- out the access of light. In determined time intervals the solutions were analyzed and the content of DCP and it's main decomposition product DPA was assessed. The stability of solutions of DCP with all the solvents kept in a refrigerator (at about 4⁰C) without light was maintained, the decomposition rate after 60 days was negligible. In contrary, DCP solutions kept at room temperature after 60 days decomposed visibly and in different rates according to a solvent (PGIEA). The most surprising finding was that DCP solutions in acetone, which was supposed to be a good solvent for the purpose of AA treatment, decomposed completely (100%) after just 45 days at room temperature. The most stable solutions at room temperature turned out to be the ones in propy- lene glycol and isopropanol. Results suggest: 1. the preferable storage condition for all DCP solutions is at a temperature of about 4⁰C without the access of light; 2. there is a limited benefit from'using acetone as a DCP solvent; 3. the novel solvent for DCP - isopropanol, showed good stability in both temperatures and has favor- able cosmetic qualities. In conclusion, authors suggest to make further investigations on DCP in isopropanol solutions in clinical studies regarding treatment of AA.

Identifiant de l'opération archéologique : 377 Date de l'opération : 1993 (FP) ; 1992 (SP) Lors de la mise en valeur du domaine de l'abbaye Saint-Georges, des recherches archéologiques ont été entreprises de 1990 à 1993. Ces fouilles font suite aux travaux de Jacques Le Maho qui aboutirent au dégagement d'un fanum en bois de la fin du Ier s. av. J.-C. Reconstruit en pierre, il a été remanié à plusieurs reprises et utilisé jusqu'au IIIe s. Le site fut, de nouveau, occupé à partir de la seconde...

Identifiant de l'operation archeologique : 377 Date de l'operation : 1993 (FP) ; 1992 (SP) Lors de la mise en valeur du domaine de l'abbaye Saint-Georges, des recherches archeologiques ont ete entreprises de 1990 a 1993. Ces fouilles font suite aux travaux de Jacques Le Maho qui aboutirent au degagement d'un fanum en bois de la fin du Ier s. av. J.-C. Reconstruit en pierre, il a ete remanie a plusieurs reprises et utilise jusqu'au IIIe s. Le site fut, de nouveau, occupe a partir de la seconde...

CARE-NMD is an EU-funded project to improve care for patients with Durchenne Muscular Dystrophy (DMD). The analysis of the current care practice is the first step to identify gaps and to plan specific measures such as training sessions for professionals and workshops for patients. For this purpose, a large cross-sectional patient-survey about the received care and quality of life of patients with DMD has been performed since September 2011 in seven European countries: Bulgaria, Czech Republic, Denmark, Germany, Hungary, Poland and the United Kingdom. A total of 1,677 patients with Duchenne Muscular Dystrophy have received questionnaires via the national patient registries. For the assessment of quality of care we defined outcome and process indicators. Outcome indicators include stage of the disease, age at loss of ambulation, ability to sit, number of hospitalisations, cardiac and pulmonary function and age at diagnosis. Process indicators comprise the frequency of medical assessments and received treatment, e.g. the use of corticosteroids, non-invasive ventilation and assistive devices. By March 31st 1,093 of 1,677 patients/families responded (66 percent). Response by country were: Bulgaria 45/73, Czech Republic 92/191, Denmark 92/131, Germany 440/545, Hungary 62/70, Poland 137/246, and for United Kingdom 223/421. Key findings about health status, received treatment, and quality of life of patients with DMD in Europe will be presented. This is the largest ever cross-sectional survey of the care and quality of life of people with DMD. The final results will provide detailed insight into the current situation of people with DMD in Europe and help to identify gaps to further improve the situation of affected patients and families.

Since 1978, excavations have been carried out in the abbey of St-Georges in St-Martin-de-Boscherville (district of Duclair, locality of Rouen). These works have permitted to bring to light and study two religious establishments which have followed each other : a collegiate founded in 1055, and a benedictine abbey built on the same site in 1113. These searches have underscored the superposition of three groups of monastic buildings, which have succeeded one another between the eleventh and the thirteenth century. The excavations have brought new elements about rural collegiate and their conversion into monastic establisments. They fit in with a search program concerning the building of religious communities in Upper Normandy., Depuis 1978, des fouilles archéologiques extensives ont eu lieu à l'abbaye St-Georges à St-Martin-de- Boscherville (canton de Duclair, arrondissement de Rouen). Ces travaux ont permis la mise au jour et l'étude de deux établissements religieux successifs : une collégiale fondée en 1055, une abbaye bénédictine installée sur le même site en 1113. Ces recherches ont mis en évidence la superposition de trois ensembles claustraux qui se sont succédé entre le XIème et le XIIIème siècle. La fouille a apporté des éléments nouveaux sur les collégiales rurales et leur transformation en établissement monastique. Elle s'inscrit dans un programme de recherche sur les établissements religieux communautaires de la Haute-Normandie., Wasylyszyn Nicolas. Abbaye Saint-Georges-de-Boscherville : de la collégiale à l'abbaye bénédictine (XIème-XVIème siècles). In: Revue archéologique de l'ouest, tome 12, 1995. pp. 147-157.

CARE-NMD aims to disseminate and implement best-practice standards of care for Duchenne muscular dystrophy (DMD) in Europe. Patient registries offer a valuable approach to engaging with the patient community, both to disseminate information and to survey their experiences. Registries permit the identification of a patient population with a precise genetic diagnosis, and are thus essential to the development of novel, mutation-specific therapeutic approaches such as exon-skipping. A core driving factor in their development has often therefore been clinical trial readiness: e.g. determining trial viability for a specific genetic mutation. However, as registries enable contact with a patient population, they also offer research opportunities outside the clinical trial domain. These include surveying availability of high-quality care and quality of life issues. Furthermore, registries permit the distribution of care information aimed at that particular audience. CARE-NMD has utilised patient registries in both of these contexts. The project has promoted knowledge of best-practice care via the translation and dissemination of the Family Guide to the care standards. This is now available in 22 languages via the CARE-NMD and TREAT-NMD websites, with 200 monthly downloads. The project has also conducted, via national patient registries in seven countries (Bulgaria, Czech Republic, Denmark, Germany, Hungary, Poland, and the UK), the largest ever survey of care and quality of life for DMD. The overall response rate is 66%, with 1100 responses received (April 2012), and national response rates of 48–89%. The data gathered provide unparalleled information on the experience of patients and families living with DMD across Europe. The use of registries also enables the return of information to the patient community, enhancing patient-led advocacy for the availability of better care, and strengthening mutual understanding between rare disease researchers and the patient community.

CARE-NMD aims to disseminate and implement best-practice standards of care for Duchenne muscular dystrophy (DMD) in Europe. As part of the project a survey of health related quality of life was to be conducted in seven countries. To select relevant methods of measurement a screening of seven existing instruments was carried out. Main criteria for selection were frequency of use, correspondence with domains in the International Classification of Functioning, Disability and Health (ICF), comparability with background population, and scope of cross cultural and geographical assessments. Three pediatric (one disease specific and two generic) and two (generic) instruments were chosen. A comprehensive questionnaire containing the selected instruments was designed and implemented through patient registries in Bulgaria, Czech Republic, Denmark, Germany, Hungary, Poland, and the UK. The overall response rate was 66%. In addition to information on the experience of 1100 European patients and families living with DMD, the data will provide important knowledge about the options and feasibilities of cross national QoL assessments in Duchenne muscular dystrophy.